Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy
- PMID: 28783807
- PMCID: PMC5726309
- DOI: 10.1001/jamapediatrics.2017.2222
Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy
Abstract
Importance: Maternal antiretroviral treatment (ART) started before conception may increase the risk for adverse birth outcomes among women with human immunodeficiency virus (HIV) infection, but whether the risk differs by ART regimen is unknown.
Objective: To compare the risk for selected birth outcomes by maternal ART regimen.
Design, setting, and participants: This observational birth outcomes surveillance study compared all live births and stillbirths with a gestational age of at least 24 weeks in 8 geographically dispersed government hospitals throughout Botswana (approximately 45% of births nationwide). Data were collected from August 15, 2014, through August 15, 2016.
Exposures: Births among HIV-infected women who started 3-drug ART regimens before their last menstrual period and did not switch or stop ART in pregnancy were considered to be ART exposed from conception.
Main outcomes and measures: The primary outcomes were any adverse birth outcome, including stillbirth, preterm birth (<37 weeks), small size for gestational age (SGA; <10th percentile of weight for gestational age) or neonatal death (<28 days from delivery), and any severe adverse outcome, including very preterm birth (<32 weeks), very SGA (<3rd percentile of weight for gestational age), stillbirth, and neonatal death.
Results: Information was available for 47 027 of 47 124 births (99.8%) at surveillance maternity hospitals (mean [SD] age of mothers, 26.86 [6.45] years). Among 11 932 HIV-exposed infants, 5780 (48.4%) were ART exposed from conception. Adverse birth outcomes were more common among HIV-exposed infants than HIV-unexposed infants (39.6% vs 28.9%; adjusted relative risk [ARR], 1.40; 95% CI, 1.36-1.44). The risk for any adverse birth outcome was lower among infants exposed from conception to tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TDF-FTC-EFV) (901 of 2472 [36.4%]) compared with TDF-FTC and nevirapine (NVP) (317 of 760 [41.7%]; ARR, 1.15; 95% CI, 1.04-1.27); TDF-FTC and lopinavir-ritonavir (TDF-FTC-LPV-R) (112 of 231 [48.5%]; ARR, 1.31; 95% CI, 1.13-1.52); zidovudine, lamivudine, and NPV (ZDV-3TC-NVP) (647 of 1365 [47.4%]; ARR, 1.30; 95% CI, 1.20-1.41); or ZDV-3TC-LPV-R (75 of 167 [44.9%]; ARR, 1.21; 95% CI, 1.01-1.45). The risk for any severe adverse outcome was also lower among infants exposed from conception to TDF-FTC-EFV (303 of 2472 [12.3%]) compared with TDF-FTC-NVP (136 of 760 [17.9%]; ARR, 1.44; 95% CI, 1.19-1.74), TDF-FTC-LPV-R (45 of 231 [19.5%]; ARR, 1.58; 95% CI, 1.19-2.11), ZDV-3TC-NVP (283 of 1365 [20.7%]; ARR, 1.68; 95% CI, 1.44-1.96), or ZDV-3TC-LPV-R (39 of 167 [23.4%]; ARR, 1.93; 95% CI, 1.43-2.60) from conception. Compared with TDF-FTC-EFV, all other regimens were associated with higher risk for SGA; ZDV-3TC-NVP was associated with higher risk of stillbirth, very preterm birth, and neonatal death; and ZDV-3TC-LPV-R was associated with higher risk for preterm birth, very preterm birth, and neonatal death.
Conclusions and relevance: Among infants exposed to ART from conception, TDF-FTC-EFV was associated with a lower risk for adverse birth outcomes than other ART regimens.
Conflict of interest statement
Figures
Similar articles
-
Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.N Engl J Med. 2018 Apr 26;378(17):1593-1603. doi: 10.1056/NEJMoa1701666. N Engl J Med. 2018. PMID: 29694825 Free PMC article.
-
Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.PLoS One. 2018 Feb 22;13(2):e0192805. doi: 10.1371/journal.pone.0192805. eCollection 2018. PLoS One. 2018. PMID: 29470508 Free PMC article.
-
Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes.AIDS. 2018 Jan 2;32(1):113-120. doi: 10.1097/QAD.0000000000001673. AIDS. 2018. PMID: 29112066 Free PMC article.
-
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.Cochrane Database Syst Rev. 2011 Jul 6;(7):CD003510. doi: 10.1002/14651858.CD003510.pub3. Cochrane Database Syst Rev. 2011. PMID: 21735394 Review.
-
Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008440. doi: 10.1002/14651858.CD008440. Cochrane Database Syst Rev. 2010. PMID: 20238370 Review.
Cited by
-
Comparative risk of adverse perinatal outcomes associated with classes of antiretroviral therapy in pregnant women living with HIV: systematic review and meta-analysis.Front Med (Lausanne). 2024 Feb 27;11:1323813. doi: 10.3389/fmed.2024.1323813. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38476445 Free PMC article.
-
Antiretroviral Therapy in Pregnancy: A 2023 Review of the Literature.Curr HIV/AIDS Rep. 2024 Feb;21(1):1-10. doi: 10.1007/s11904-024-00688-y. Epub 2024 Jan 26. Curr HIV/AIDS Rep. 2024. PMID: 38277098 Free PMC article. Review.
-
Fetal growth assessed via ultrasound in relation to maternal HIV infection status and antiretroviral regimens.AIDS. 2024 Mar 15;38(4):567-577. doi: 10.1097/QAD.0000000000003796. Epub 2023 Nov 21. AIDS. 2024. PMID: 37991521
-
No increased in utero and peripartum HIV acquisition risk in HIV-exposed preterm infants.South Afr J HIV Med. 2023 Oct 19;24(1):1509. doi: 10.4102/sajhivmed.v24i1.1509. eCollection 2023. South Afr J HIV Med. 2023. PMID: 37928500 Free PMC article.
-
The impact of free antiretroviral therapy for pregnant non-citizens and their infants in Botswana.J Int AIDS Soc. 2023 Oct;26(10):e26161. doi: 10.1002/jia2.26161. J Int AIDS Soc. 2023. PMID: 37885157 Free PMC article.
References
-
- World Health Organization Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization Programme, Geneva, Switzerland. http://www.who.int/hiv/pub/arv/arv-2016/en/. June 2016. Accessed January 2, 2017.
-
- UNICEF. For every child, end AIDS: seventh stocktaking report, 2016. http://st7.childrenandaids.org/sites/default/files/STR%202016%20Report%2.... December 2016. Accessed January 2, 2016.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical